Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STELAZINE vs ATIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Schizophrenia,Short-term treatment of generalized non-psychotic anxiety (off-label)
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Hepatic via CYP450 enzymes (primarily CYP2D6); also undergoes N-demethylation and sulfoxidation.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
92-97% bound to albumin and alpha-1 acid glycoprotein.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
Approximately 18-30 L/kg (0.5-1.5 L/kg). Clinical meaning: Extensive tissue distribution with high CNS penetration.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Oral: ~40% (due to first-pass metabolism); IM: 100%.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
No specific dose adjustment recommended; use caution in severe renal impairment.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Children 6-12 years: 1 mg 1-2 times daily; increase gradually up to 15 mg/day. Children >12 years: adult dosing.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Initiate at 1-2 mg twice daily; titrate slowly due to increased sensitivity and risk of orthostatic hypotension and extrapyramidal symptoms.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
Increased mortality in elderly patients with dementia-related psychosis.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, leukopenia/neutropenia/agranulocytosis, seizure threshold lowering, anticholinergic effects, hypotension, cholestatic jaundice, ocular changes (corneal/lenticular deposits).
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Comatose states, CNS depression (e.g., barbiturates, alcohol), bone marrow depression, blood dyscrasias, hepatic disease, hypersensitivity to phenothiazines.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
Avoid alcohol and CNS depressants. Grapefruit juice may increase drug levels; avoid concurrent use. Limit caffeine intake. No specific dietary restrictions, but monitor weight gain due to increased appetite.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimesters: Risk of extrapyramidal symptoms, jaundice, and hyperreflexia in neonates with late exposure. Case reports of neonatal withdrawal and EPS. Not a known major teratogen but use only if benefits outweigh risks.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
Excreted in breast milk in small amounts; relative infant dose est. ~0.1-0.5% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, EPS, and poor feeding. Generally considered compatible with breastfeeding with caution.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Increased clearance in pregnancy may necessitate dose titration. Start at low end of dosing range; increase gradually based on response and tolerability. Monitor for relapse. Postpartum dose may need reduction due to restored clearance. No specific PK studies available; clinical judgment advised.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
Extrapyramidal symptoms (EPS) are common; use benztropine prophylactically in young males. Monitor for QT prolongation, especially in elderly. Avoid in patients with history of tardive dyskinesia. Can cause orthostatic hypotension; titrate slowly. Neuroleptic malignant syndrome (NMS) rare but serious; discontinue immediately if hyperthermia, rigidity, autonomic instability occur.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
Take exactly as prescribed; do not stop abruptly.,May cause dizziness upon standing; rise slowly from sitting or lying down.,Report any involuntary muscle movements, stiffness, or tremors to your doctor.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; use caution when driving or operating machinery.,Notify your doctor if you experience rapid heartbeat, fainting, or fever with muscle rigidity.,Avoid exposure to extreme heat (can impair body temperature regulation).,Store at room temperature away from light and moisture.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STELAZINE vs ATIVAN, answered by our medical review team.
STELAZINE is a Phenothiazine Antipsychotic that works by Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.. ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STELAZINE and ATIVAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STELAZINE is: Adults: 2-10 mg orally twice daily; maximum 40 mg/day.. The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STELAZINE and ATIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STELAZINE is classified as Category C. First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimester. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.